This start-up has developed the iBreastExam, designed to be low-cost breast health test to be used by community workers in low resource settings. Specifically, it is designed to address the rising incidence of breast cancer in developing countries where women have limited or no access to breast cancer screening services. The iBreastExam is a wireless scanner, designed to be highly portable and easy to use. Using it is painless and radiation free, and takes less than 5 minutes to complete. The device can be used by any doctor or health worker and the results are available at the point-of-care. iBreastExam assesses differences in tissue elasticity between malignant and non-cancerous breast tissue, and its tactile sensor measures stiffness and tissue compression when applied to the skin.


A clinical study conducted in India reported that the test maintained high specificity and outperformed an expert clinician who conducted a conventional clinical breast examination. All malignant lesions were identified by the device, while the clinician failed to identify a non-palpable lesion.


An estimated 1.7million women will be diagnosed with breast cancer in 2020, and most of those will be in the developing world.


The company has received $4.2m in funding to date, with investors including Unitus Ventures, Kiran Mazumdar-Shaw and Aarin Capital.